Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.

Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V.

Brain Pathol. 2012 Mar;22(2):159-74. doi: 10.1111/j.1750-3639.2011.00515.x.

PMID:
21790828
2.

NK cells recognize and kill human glioblastoma cells with stem cell-like properties.

Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, Bottino C.

J Immunol. 2009 Mar 15;182(6):3530-9. doi: 10.4049/jimmunol.0802845.

3.

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L.

Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.

4.

Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.

Broadley KW, Hunn MK, Farrand KJ, Price KM, Grasso C, Miller RJ, Hermans IF, McConnell MJ.

Stem Cells. 2011 Mar;29(3):452-61. doi: 10.1002/stem.582.

5.

A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling.

Yang F, Nam S, Brown CE, Zhao R, Starr R, Ma Y, Xie J, Horne DA, Malkas LH, Jove R, Hickey RJ.

PLoS One. 2014 Apr 14;9(4):e94443. doi: 10.1371/journal.pone.0094443. Erratum in: PLoS One. 2014;9(6):e100708. Ma, Yuelong [added]; Xie, Jun [added].

6.

Targeting role of glioma stem cells for glioblastoma multiforme.

Zhang X, Zhang W, Mao XG, Zhen HN, Cao WD, Hu SJ.

Curr Med Chem. 2013;20(15):1974-84. Review.

PMID:
23317162
7.

Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.

Persano L, Rampazzo E, Basso G, Viola G.

Biochem Pharmacol. 2013 Mar 1;85(5):612-22. doi: 10.1016/j.bcp.2012.10.001. Review.

PMID:
23063412
8.

The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture.

Haley EM, Kim Y.

Cancer Lett. 2014 Apr 28;346(1):1-5. doi: 10.1016/j.canlet.2013.12.003. Review.

9.

Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.

Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, Meling T, Murrell W, Vik Mo EO, Langmoen IA.

Oncotarget. 2015 Sep 22;6(28):26192-215. doi: 10.18632/oncotarget.4613.

10.

The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.

Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ.

Neuro Oncol. 2014 Jan;16(1):29-37. doi: 10.1093/neuonc/not139.

11.

IGFBP2 promotes glioma tumor stem cell expansion and survival.

Hsieh D, Hsieh A, Stea B, Ellsworth R.

Biochem Biophys Res Commun. 2010 Jun 25;397(2):367-72. doi: 10.1016/j.bbrc.2010.05.145.

PMID:
20515648
12.

Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.

Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG.

Oncotarget. 2015 Apr 20;6(11):8788-806.

13.

Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway.

Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, Wexler E, Saigusa K, Nakamura Y, Laks DR, Mischel PS, Viapiano M, Kornblum HI.

Neuro Oncol. 2011 Jun;13(6):622-34. doi: 10.1093/neuonc/nor023.

14.

Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.

Garner JM, Ellison DW, Finkelstein D, Ganguly D, Du Z, Sims M, Yang CH, Interiano RB, Davidoff AM, Pfeffer LM.

PLoS One. 2015 May 8;10(5):e0125838. doi: 10.1371/journal.pone.0125838. Erratum in: PLoS One. 2015;10(12):e0145052.

15.

Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.

Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, Guichet PO, Bian X, Armesilla AL, Darling JL, Wang W.

Br J Cancer. 2012 Oct 23;107(9):1488-97. doi: 10.1038/bjc.2012.442.

16.

Targeting glioblastoma stem cells: cell surface markers.

He J, Liu Y, Lubman DM.

Curr Med Chem. 2012;19(35):6050-5. Review.

PMID:
22963566
17.

Brain tumor stem cells as research and treatment targets.

Hide T, Takezaki T, Nakamura H, Kuratsu J, Kondo T.

Brain Tumor Pathol. 2008;25(2):67-72. doi: 10.1007/s10014-008-0237-5. Review.

PMID:
18987831
18.

Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications.

Yang L, Lin C, Wang L, Guo H, Wang X.

Exp Cell Res. 2012 Nov 15;318(19):2417-26. doi: 10.1016/j.yexcr.2012.07.017. Review.

PMID:
22906859
19.

Collateral damage control in cancer therapy: defining the stem identity in gliomas.

Hsieh D.

Curr Pharm Des. 2011;17(23):2370-85. Review.

PMID:
21827417
20.

MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.

Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, Nardini D, Sobol RW, Chow LM, Kornblum HI, Waclaw R, Beullens M, Nakano I.

Stem Cells. 2013 Jun;31(6):1051-63. doi: 10.1002/stem.1358.

Items per page

Supplemental Content

Support Center